The need to improve efficiency and comply with regulatory and geographical demands is driving the third-party clinical payment industry, say Greenphire, CFS and Clinverse.
Drugmakers and academics will have to upload the results of trials run in Europe to a public database under a provisional deal agreed in the European Parliament earlier today.
Algorithme Pharma has increased early stage patient access by teaming with a Montreal hospital, and says it provides a breadth of therapeutic areas not normally associated with mid-sized CROs.
Trust, transparency and end-to-end participation are just some of the reasons Merck Serono says its exclusive strategic partnership with Quintiles is the “first of its kind.”
Strategic partnerships are “the next phase” of sponsor-CRO relations, according to Parexel, and on top of saving pharma on oversight costs will reshape the industry.
Smartphones are changing the role of the patient in clinical trials and can be used for industry success, Pfizer and technology provider firm Exco InTouch said at PCT 2013.
Quintiles issued a mixed set of revised financial predictions for 2013, increasing its earnings per share forecast after a surge of new business wins and narrowing its service revenue.
Covance produced solid Q3 results as expected by analysts though whether the CRO can fire both early and late stage development cylinders at once remains a question.
Parexel has teamed up with Japanese trial management services firm Fuijitsu Systems West in an agreement that underlines the CROs eClinical growth ambitions in Asia.
CRO Quintiles says it is in favor of the voluntary sharing of de-identified and masked clinical and preclinical data that protects the interests of research participants and proprietary data, though it stopped short of calling for the public release of...
Private equity group Parthenon Capital Partners has acquired eClinical services firm Bracket from US pharmacy benefit management organization Express Scripts.
China’s top CRO Wuxi Apptec has purchased a remote clinical trial monitoring tool that will allow its toxicology clients log onto a secure Web site to view data from on-going studies.
AstraZeneca has selected the Sarah Cannon Research Institute (SCRI) to help develop oncology compounds using molecular profiling to more accurately predict a patient's response.
Sponsors are piling on more responsibilities for their CRO partners, but the question of how that will translate into increases in risk and profit sharing is a point of contention.
With small companies and biotechs increasingly discovering new products, there are big opportunities for contract development and manufacturing organisations (CDMO), says ex-GSK expert.
PRA International says technology and IT innovation will help it compete with rivals that have moved their service centres to cheaper locations in the East to cut costs.
Eisai has tasked a new exec with making trials more likely to succeed just a few months after its candidate ovarian cancer blockbuster failed at Phase III.
Welcome to Outsourcing-Pharma.com’s round-up of CRO focused partnerships and collaborations including news from Particle Science and Agility Clinical Partners.
CROs invest in scope and scale while private-equity groups buy firms they can expand according to Fairmount Partners’ managing director, Neal McCarthy.
Clinical trials made public by Pfizer did not match internal reports or reflect what was done in studies of the seizure drug gabapentin say researchers calling for revision of journal publishing codes.
The US Food and Drug Administration (FDA) has adopted a practical Q&A from the International Conference on Harmonisation (ICH) to help sponsors and CROs craft clinical study reports (CSRs), an expert says.
